ChemicalBook > Product Catalog >API >Inhibitors >Crizotinib

Crizotinib

Crizotinib Suppliers list
Company Name: Shanghai Bojing Chemical Co.,Ltd.
Tel: +86-21-37122233
Email: Candy@bj-chem.com
Products Intro: Product Name:Crizotinib
CAS:877399-52-5
Purity:99% Package:1g;100g;500g;1Kg/Foil bag
Company Name: TianYuan Pharmaceutical CO.,LTD
Tel: +86-755-23284190 13684996853
Email: sales@tianpharm.com
Products Intro: Product Name:Crizotinib
CAS:877399-52-5
Purity:99% Package:10g 100g 200g 500g 1kg 5kg per barrel
Company Name: Nanjing Gold Pharmaceutical Technology Co. Ltd.
Tel: 025-84209270 15906146951
Email: wgp@nanjing-pharmaceutical.com
Products Intro: Product Name:Crizotinib
CAS:877399-52-5
Purity:99% Package:1000KG;;100KG;10KG;5KG;1KG
Company Name: Jurong Coupling Biotechnology Co., Ltd.
Tel: 13656108824
Email: coupling278191416@hotmail.com
Products Intro: Product Name:Crizotinib
CAS:877399-52-5
Purity:99% HPLC Package:5KG;1KG
Company Name: zhangjiagang vinsce bio-pharm. limited.
Tel: 86-512-58389969
Email: sales1@swellxin.com
Products Intro: Product Name:3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine
CAS:877399-52-5
Purity:98% Package:10g;50g;500g;1000g;25kg;50kg

Lastest Price from Crizotinib manufacturers

  • Crizotinib
  • US $0.00-0.00 / KG
  • 2020-07-22
  • CAS:877399-52-5
  • Min. Order: 1g
  • Purity: 99%
  • Supply Ability: 500kg/month
  • Crizotinib
  • US $7.00 / KG
  • 2019-09-02
  • CAS: 877399-52-5
  • Min. Order: 1KG
  • Purity: 99%
  • Supply Ability: JD 482
  • Crizotinib
  • US $7.00 / KG
  • 2019-07-06
  • CAS: 877399-52-5
  • Min. Order: 1KG
  • Purity: 99%
  • Supply Ability: 100KG

Related articles

Crizotinib Basic information
Biological Activity Mechanism of action side effects
Product Name:Crizotinib
Synonyms:3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-2-aMinopyridine;(R)-3-[1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H- pyrazol-4-yl)pyridin-2-ylaMine;[3-[[(R)-1-(2,6-Dichloro-3- fluorophenyl)ethyl]oxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-yl]aMine;2-PyridinaMine, 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-;Crozotinib;Crizotinib,PF-02341066;Xalkori;Crizotinib Xalkori
CAS:877399-52-5
MF:C21H22Cl2FN5O
MW:450.343
EINECS:638-814-9
Product Categories:API;API;Inhibitor;Aromatic;Chiral Reagents;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pfizer Compounds;Pharmaceuticals;Anti-cancer & immunity
Mol File:877399-52-5.mol
Crizotinib Structure
Crizotinib Chemical Properties
Melting point 192 °C
Boiling point 599.2±50.0 °C(Predicted)
density 1.47±0.1 g/cm3(Predicted)
storage temp. room temp
pka9.81±0.10(Predicted)
form powder
color white to tan
CAS DataBase Reference877399-52-5
Safety Information
Safety Statements 24/25
RIDADR UN 3077 9 / PGIII
WGK Germany 3
HazardClass IRRITANT
HS Code 29333990
MSDS Information
Crizotinib Usage And Synthesis
Biological ActivityPotent inhibitor of c-MET and anaplastic lymphoma kinase (ALK) (cell IC50 values are 8.0 and 20 nM respectively). Selective for c-MET and ALK against >120 different kinases. Displays antitumor efficacy in multiple tumor models; inhibits c-MET-dependent proliferation, migration and invasion of human tumor cells in vitro. Orally bioavailable.
Mechanism of actionCrizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and Recepteur d’Origine Nantais (RON). Translocations can affect the ALK gene resulting in the expression of oncogenic fusion proteins. The formation of ALK fusion proteins results in the activation and dysregulation of the gene's expression and signaling, which can contribute to increased cell proliferation and survival in tumors expressing these proteins. Crizotinib demonstrates concentration-dependent inhibition of ALK and c-Met phosphorylation in cell-based assays using tumor cell lines, and also demonstrates antitumor activity in mice bearing tumor xenografts that express EML4-or NPM-ALK fusion proteins or c-Met.Crizotinib is a multitargeted small molecule tyrosine kinase inhibitor, which had been originally developed as an inhibitor of the mesenchymal epithelial transition growth factor (c-MET); it is also a potent inhibitor of ALK phosphorylation and signal transduction. This inhibition is associated with G1-S phase cell cycle arrest and induction of apoptosis in positive cells in vitro and in vivo. Crizotinib also inhibits the related ROS1 receptor tyrosine kinase.
References
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3876666/
side effectscrizotinib (Xalkori) is an oral receptor tyrosine kinase inhibitor indicated for the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC). Common side effects with Xalkori use include upper respiratory infection, nausea, vomiting, stomach pain, decreased appetite, insomnia, dizziness, tired feeling, diarrhea, constipation, rash or itching, cold symptoms (stuffy nose, sneezing, sore throat), numbness or tingling, or swelling in your hands or feet.
http://www.rxlist.com/xalkori-side-effects-drug-center.htm
DescriptionIn August 2011, the United States FDA approved crizotinib (PF- 02341066) for the treatment of anaplastic lymphoma kinase (ALK) rearranged non-small-cell lung cancer (NSCLC). Crizotinib is a dual ATP competitive inhibitor of tyrosine kinases c-MET (Mesenchymal-Epithelial Transition Factor) kinase (cellular IC50=8 nM) and ALK (cellular IC50=20 nM), both of which are important targets for cancer chemotherapy. When crizotinib was tested for selectivity versus other kinases it was found to have enzyme IC50's within 100-fold multiples of c-MET for 13 of the 120 kinases tested. In cellular assays, crizotinib was found to inhibit RON (recepteur d’origine nantais) kinase with a 10-fold selectivity window over c-MET.
Chemical PropertiesWhite Solid
OriginatorPfizer (United States)
UsesA potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). A potential antitumor agent.
UsesCrizotinib is a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). Crizotinib is a potential antitumor agent.
UsesPF-2341066 (Crizotinib) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM, respectivley
DefinitionChEBI: A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients wi h locally advanced or metastatic non-small cell lung cancer (NSCLC)
IndicationsCrizotinib (Xalkori(R), Pfizer), approved in 2011, was the first approved inhibitor targeting anaplastic lymphoma kinase (ALK). ROS protooncogene 1-encoded kinase (ROS1) of the tyrosine kinase insulin receptor class and MET proto-oncogene-encoded kinase of the hepatocyte growth factor receptor (HGFR) class are other kinases targeted by crizotinib.When approved in 2011, crizotinib was the first drug specifically targeting NSCLC patients. However, resistance to crizotinib was usually observed in approximately 8 months after initial application and more than half of crizotinib-treated patients experienced gastrointestinal side effects. In 2016,crizotinib was additionally approved for ROS1-positive NSCLC by FDA.
Brand nameXalkori
Crizotinib Preparation Products And Raw materials
Tag:Crizotinib(877399-52-5) Related Product Information
Cabozantinib Malate 918504-65-1 1110813-31-4 Afatinib (BIBW 2992) PLERIXAFOR 201530-41-8 9-ethyl-6,6-diMethyl-8-(4-Morpholinopiperidin-1-yl)-11-oxo-5a,6,11,11a-tetrahydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride Nintedanib Ethanesulfonate Salt (R)-5-bromo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine 4-(4-Bromopyrazol-1-yl)piperidine-1-carboxylic acid tert-butyl ester (S)-1-(2,6-Dichloro-3-fluorophenyl)ethanol (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine Bortezomib Ceritinib Trametinib Erlotinib hydrochloride N-(3-(5-(4-Chlorophenyl)-1H-pyrrolo[2,3-B]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonaMide Olaparib